Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
camoteskimab (AVTX-007) / Apollo Therap
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis	Recruiting	2	60	Canada, US	Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo	Apollo Therapeutics Ltd	Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic	02/25	06/25
NCT04752371: A Study to Evaluate Camoteskimab in Participants With Still's Disease	Terminated	1b	5	Europe, US, RoW	Camoteskimab (CERC-007, AVTX-007, AEVI-007)	Apollo Therapeutics Ltd	Adult Onset Still's Disease	05/22	05/22
α1 anti-trypsin deficiency therapeutic / Apollo Therap
No trials found
Chronic obstructive pulmonary disease therapeutic / Apollo Therap
No trials found